Sanofi SA (EPA:SAN) has been given a consensus rating of “Hold” by the seventeen brokerages that are covering the firm. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is €87.13 ($96.81).

SAN has been the topic of a number of recent research reports. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Sanofi SA in a report on Tuesday, October 4th. BNP Paribas set a €78.00 ($86.67) price target on Sanofi SA and gave the stock a “neutral” rating in a report on Wednesday, September 14th. Deutsche Bank AG set a €95.00 ($105.56) price target on Sanofi SA and gave the stock a “buy” rating in a report on Thursday. Jefferies Group set a €74.00 ($82.22) price target on Sanofi SA and gave the stock a “neutral” rating in a report on Thursday. Finally, Independent Research GmbH set a €77.00 ($85.56) price target on Sanofi SA and gave the stock a “neutral” rating in a report on Thursday, June 30th.

Sanofi SA (EPA:SAN) opened at 68.41 on Friday. The company’s 50 day moving average price is €25.95 and its 200-day moving average price is €25.75. Sanofi SA has a one year low of €62.50 and a one year high of €93.82. The company has a market cap of €88.04 billion and a P/E ratio of 21.27.

Sanofi SA Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.